London, United Kingdom

Michael Derek Waterfield

USPTO Granted Patents = 31 


Average Co-Inventor Count = 5.1

ph-index = 9

Forward Citations = 572(Granted Patents)


Location History:

  • Berkshire, GB (1997)
  • Speen Newbury, GB (1998)
  • Newbury, GB (1996 - 2011)
  • London, GB (1990 - 2014)

Company Filing History:


Years Active: 1990-2014

Loading Chart...
Loading Chart...
31 patents (USPTO):Explore Patents

Title: Michael Derek Waterfield: Innovator in Molecular Biology

Introduction

Michael Derek Waterfield, based in London, GB, is a remarkable inventor with an impressive portfolio of 31 patents. His work primarily focuses on molecular biology and therapeutic innovations that have the potential to impact medical research and treatment significantly.

Latest Patents

Among his latest patents is the invention titled "Truncated variant of the mammalian target for rapamycin (MTOR) protein." This invention pertains to mTORbeta, a splice form of mTOR, along with nucleic acids encoding mTOR beta and antibodies against it. The patent further details methods of producing mTOR beta and screening for agents that modulate its expression or activity. Importantly, it also outlines methods for treating diseases associated with aberrant mTOR beta expression.

Another significant patent from Waterfield is titled "Glial mitogenic factors, their preparation and use." This patent details the characterization and purification of DNA encoding several polypeptides useful for stimulating glial cell (particularly Schwann cell) mitogenesis, as well as for treating glial cell tumors. It includes methods for synthesizing, purifying, and testing both known and novel polypeptides for use as therapeutic and diagnostic aids. Additionally, it describes the use of these polypeptides for preparing antibody probes useful in the context of diseases involving glial cells.

Career Highlights

Waterfield has collaborated with prestigious institutions and companies during his career. He has notably worked at the Ludwig Institute for Cancer Research Limited and Acorda Therapeutics, Inc., contributing to advancements in cancer research and therapeutic development.

Collaborations

Throughout his career, Michael Waterfield has collaborated with distinguished professionals, including Ian D. Hiles and Andrew David Goodearl. Their teamwork has likely contributed to the innovative solutions and research breakthroughs in which Waterfield has engaged.

Conclusion

Michael Derek Waterfield remains a prominent figure in the field of molecular biology with a notable array of patents that promise to enhance our understanding and treatment of various diseases. His dedication to innovation continues to inspire researchers and professionals across multiple disciplines.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…